NDA 213756 · Astrazeneca
Koselugo
Selumetinib Sulfate · Oral · Kinase Inhibitor
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: May 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Apr 10, 2020
Approved uses
4
Original approval plus efficacy supplements
Registered trials
132
7 Phase 3, 8 recruiting
FAERS reports
1,684
1,358 serious, 103 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 26, 2026.
KOSELUGO is indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN) [see Dosage and Administration (2) ]. KOSELUGO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). ( 1 )
Mechanism: Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). MEK1/2 proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. Both MEK and ERK are critical components of the RAS-regulated RAF-MEK-ERK pathway, which is often activated in different types of cancers. In genetically modified mouse models of NF1 that generate neurofibromas that recapitulate the genotype and phenotype of human NF1, oral dosing of selumetinib inhibited ERK phosphorylation, and reduced neurofibroma numbers, volume, and proliferation.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 19, 2025 Supplement 6 · Efficacy OrphanLabelLetter
- Sep 10, 2025 Supplement 5 · Efficacy · priority review OrphanLabelLetter
- Jan 24, 2024 Supplement 4 · Efficacy LetterLabel
- Apr 10, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
- KOSELUGO · SELUMETINIB SULFATE EQ 25MG BASE · CAPSULE, ORAL · Prescription
- KOSELUGO · SELUMETINIB SULFATE EQ 10MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Selumetinib" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05564377 · 2,900 participants (planned) · Start Apr 7, 2023 · Primary completion Jul 1, 2030
Drug: Alpelisib; Binimetinib and 13 more · For: Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 and 12 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 484 sites in all
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerPivotal-lookingActive, not recruiting
UNICANCERAcademic, hospital or other
NCT02299999 · 1,460 participants · Start Apr 7, 2014 · Primary completion Dec 2022
Drug: AZD2014; AZD4547 and 17 more · For: Metastatic Breast Cancer
Sites: Angers, France; Avignon, France; Bordeaux, France · 25 sites in all
National Cancer Institute (NCI)NIH
NCT03155620 · 1,377 participants · Start Jul 31, 2017 · Primary completion Mar 31, 2025
Drug: Ensartinib; Erdafitinib and 11 more · For: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma and 42 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Mesa, Arizona · 172 sites in all
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsPivotal-lookingCompleted
UNICANCERAcademic, hospital or other
NCT02117167 · 999 participants · Start Apr 23, 2014 · Primary completion Dec 22, 2018
Drug: AZD2014; AZD4547 and 9 more · For: Non-small Cell Lung Cancer Metastatic
Sites: Avignon, France; Besançon, France; Bobigny, France · 37 sites in all
National Cancer Institute (NCI)NIH
NCT01306045 · 647 participants · Start Feb 8, 2011 · Primary completion Feb 12, 2014
Drug: AZD6244; MK-2206 and 3 more · For: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell Lung; Carcinoma, Thymic
Sites: Bethesda, Maryland
- Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLCPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT01933932 · 510 participants · Start Sep 25, 2013 · Primary completion Jun 7, 2016
Drug: Selumetinib; Docetaxel and 2 more · For: Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Sites: Aurora, Colorado; Pembroke Pines, Florida; Atlanta, Georgia · 197 sites in all
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT02813135 · 472 participants (planned) · Start Aug 3, 2016 · Primary completion Feb 2031
Drug: Ribociclib; Topotecan and 22 more · For: Pediatric Cancer
Sites: Copenhagen, Denmark; Villejuif, France; Angers, France · 23 sites in all
University of BirminghamAcademic, hospital or other
NCT02664935 · 423 participants · Start May 13, 2015 · Primary completion Nov 29, 2023
Drug: AZD4547; Vistusertib and 9 more · For: Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma
Sites: Aberdeen, United Kingdom; Belfast, United Kingdom; Birmingham, United Kingdom · 25 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- rash140
- off label use121
- blood creatine phosphokinase increased104
- paronychia96
- diarrhoea92
- acne85
- dermatitis acneiform84
- nausea84
- fatigue82
- alopecia70
- vomiting67
- death57
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 7 |
| 2017 | 4 |
| 2018 | 5 |
| 2019 | 1 |
| 2020 | 55 |
| 2021 | 97 |
| 2022 | 168 |
| 2023 | 191 |
| 2024 | 351 |
| 2025 | 379 |
| 2026 | 405 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Koselugo (Selumetinib Sulfate)
2024 spending
$22.4M
Beneficiaries
157
1,175 claims
Per beneficiary
$142,431
$182.85 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,507,793 |
| 2021 | $8,545,575 |
| 2022 | $10,000,943 |
| 2023 | $14,917,273 |
| 2024 | $22,361,712 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Selumetinib in Children with Inoperable Plexiform Neurofibromas.
Gross AM, Wolters PL, Dombi E, et al. · N Engl J Med 2020 · Clinical Trial, Phase II, Research Support, N.I.H., Intramural
- Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study.
Chen AP, Coyne GO, Wolters PL, et al. · Lancet 2025 · Randomized Controlled Trial, Multicenter Study
- Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial.
Gross AM, O'Sullivan Coyne G, Dombi E, et al. · Nat Med 2025 · Clinical Trial, Phase II, Research Support, N.I.H., Extramural
- Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma.
Kim H, Yoon HM, Kim EK, et al. · Neuro Oncol 2024 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Dombi E, Baldwin A, Marcus LJ, et al. · N Engl J Med 2016 · Clinical Trial, Phase I, Research Support, N.I.H., Intramural
- Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.
Gross AM, Dombi E, Wolters PL, et al. · Neuro Oncol 2023 · Clinical Trial, Phase II, Clinical Trial, Phase I
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.